WESTLAKE VILLAGE, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will present at the TD Cowen 46th Annual Health Care Conference, taking place March 2-4, 2026, in Boston. Details for the Company’s participation are as follows:     Fireside Chat: Monday, March 2, 2026 at 1:50 p.m. ET The webcast for this conference ma ...

WESTLAKE VILLAGE, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will present at the TD Cowen 46th Annual Health Care Conference, taking place March 2-4, 2026, in Boston. Details for the Company’s participation are as follows: Fireside Chat: Monday, March 2, 2026 at 1:50 p.m. ET The webcast for this conference may be ...

Core Insights - Arcutis Biotherapeutics Inc. is a prominent biopharmaceutical company focused on innovative dermatological treatments, particularly its leading product ZORYVE® (roflumilast), which has shown significant revenue growth [1] Financial Performance - In Q4 2025, Arcutis reported earnings of $0.13 per share, exceeding the Zacks Consensus Estimate of $0.03 per share, resulting in an earnings surprise of +290.39% [2][6] - The company's revenue for Q4 2025 reached $129.5 million, surpassing the Zacks Consensus Estimate by 11.93%, and marking an 84% increase from $71.36 million in Q4 2024 [3][6] - ZORYVE® generated net product revenue of $127.5 million in Q4 2025, reflecting an 84% increase from Q4 2024 and a 29% rise from Q3 2025 [3][6] Growth Prospects - Arcutis is expanding its product portfolio, with positive topline data from the INTEGUMENT-INFANT Phase 2 trial of ZORYVE cream 0.05% for children with mild to moderate atopic dermatitis, and plans to submit a Supplemental New Drug Application (sNDA) in Q2 2026 [4] - The company is enhancing its dermatology sales force and implementing a targeted commercialization strategy aimed at primary care and pediatric healthcare providers [5] - Arcutis raised its 2026 full-year net product sales guidance to between $480 million and $495 million, indicating strong confidence in its growth trajectory [5][6]

I hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation for the rigor and challenges behind drug development, which I now bring into my work as an investor and analyst. For the past five years, I have been active in the investing space, with the last four years dedicated to ...

Core Viewpoint - Arcutis Biotherapeutics, Inc. reported quarterly earnings of $0.13 per share, significantly exceeding the Zacks Consensus Estimate of $0.03 per share, and showing an improvement from a loss of $0.09 per share a year ago, indicating a strong earnings surprise of +290.39% [1] Financial Performance - The company achieved revenues of $129.5 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 11.93%, and showing a substantial increase from year-ago revenues of $71.36 million [2] - Over the last four quarters, Arcutis Biotherapeutics has consistently exceeded consensus EPS estimates, achieving this four times [2] Stock Performance and Outlook - Despite the positive earnings report, Arcutis Biotherapeutics shares have declined approximately 7.1% since the beginning of the year, contrasting with the S&P 500's gain of 0.7% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the sustainability of the recent earnings numbers [3][4] Earnings Estimates and Industry Context - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $94.6 million, while for the current fiscal year, it is $0.38 on revenues of $470.02 million [7] - The Medical - Biomedical and Genetics industry, to which Arcutis belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable industry outlook that could positively influence stock performance [8]

Arcutis Biotherapeutics (NasdaqGS:ARQT) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsBrian Schoelpkopf - VP of Investor RelationsDouglas Tsao - Managing DirectorFrank Watanabe - President and CEOIkenna Okafor - Biotechnology Equity ResearchLata Vyravan - CFOPatrick Burnett - CMORitch Law - VP in Global Investment ResearchSeamus Fernandez - Senior Managing DirectorSerge Belanger - Managing DirectorTodd Edwards - CCOConference Call ParticipantsJudah Frommer - Executive Director, Sen ...

Arcutis Biotherapeutics (NasdaqGS:ARQT) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsBrian Schoelpkopf - VP of Investor RelationsDouglas Tsao - Managing DirectorFrank Watanabe - President and CEOIkenna Okafor - Biotechnology Equity ResearchLata Vyravan - CFOPatrick Burnett - CMORitch Law - VP in Global Investment ResearchSeamus Fernandez - Senior Managing DirectorSerge Belanger - Managing DirectorTodd Edwards - CCOConference Call ParticipantsJudah Frommer - Executive Director, Sen ...

Arcutis Biotherapeutics (NasdaqGS:ARQT) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Speaker0Ladies and gentlemen, thank you for standing by. Welcome to the Arcutis Biotherapeutics Inc's fourth quarter fiscal year 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will hear an automated mes ...

4th Quarter and Full Year 2025 Financial Results Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to management. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other factors including, but not limited to, those related to the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; our plans to develop and commercialize targeted t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 001-39186 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Inco ...